‘FDA Is Not the Villain:’ Study Highlights Need For Post-Market Focus To Spur Antibiotics
Executive Summary
A study of drug approvals over more than three decades shows antimicrobials, including antibacterials, had consistently shorter development and review times than other types of products. While antibacterials were less likely to participate in special US FDA programs designed to help along review, experts said reimbursement reform, not new regulatory flexibility, is needed to help address the crisis of drug-resistant infections.
You may also be interested in...
Antibiotic Development: HHS Not Yet Sold On ‘Pull’ Incentives
As HHS develops strategic framework to combat antibiotic resistance, post-market financial incentives may not be included, despite prominent government panels recommending the idea years ago and GAO urging the department to do so in a just-released report. Stakeholders told that GAO reimbursement reform won't be enough to spur a strong antibiotic pipeline.
Ketek's Political Fallout
The negative attention from Capitol Hill over the approval of the antibiotic Ketek is impacting much more than the commercial prospects of a single drug: it's making FDA reviewers think twice about other applications.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.